Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Ferring Gene Therapy, Fujifilm Cell Product Inch Closer to Approval
A Japanese health ministry panel on April 18 recommended approval for Ferring Pharmaceuticals’ bladder cancer gene therapy and Fujifilm Toyama Chemical’s autologous stem cell therapy for meniscus injuries. The Pharmaceutical Affairs Council’s Committee on Regenerative Medicine Products, Biological Products and…
To read the full story
Related Article
- Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
May 12, 2026
- Fujifilm Bags Japan Approval for Meniscus Regenerative Therapy
May 11, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
- Japan PIII Trial Begins for Kagoshima University Spinout’s Oncolytic Virus
November 27, 2025
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
- Fujifilm Seeks Japan Nod for Stem Cell Therapy for Meniscus Injuries
May 15, 2025
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…